Evicenter
MarkdownMedical informationP&T meetings
Envudeucitinib (ESK-001)

Moderate-to-severe plaque psoriasis

Also known as FTP-637
Manufacturer
Alumis
Launch
Not announced
Last updated
277 sources

Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care

TNF inhibitors

10 evidence topics · 8 sources

Decision aid: TNF inhibitors
AgentRoughly what proportion of people are clear or nearly clear (PASI 90) in the first 6 months?What is the likelihood of staying on this treatment for more than 1 year?
Adalimumab“31%”“74–76% chance”
Certolizumab pegol“24%”“Not known at present”
Etanercept“18%”“67–73% chance”
Infliximab“91%”“54–74% chance”
Network meta-analysis: infliximab and other TNF inhibitors